Roidipedia.Compound reference & reporting
06 AUG 2026
CompoundsAnabolic steroid Methylboldenone
Anabolic steroidAndrogenOral17-alpha-alkylatedDesigner steroidBoldenone derivative

Methylboldenone

Also known as 17a-Methylboldenone · Methyl-1,4-androstadien-17b-ol-3-one

Methylboldenone (17-alpha-methylboldenone) is an orally active, C17-alpha-alkylated derivative of boldenone. It combines boldenone's diene structure with a methyl group for oral bioavailability, producing a hepatotoxic oral anabolic that surfaced in the grey-market designer/prohormone scene. Human study is essentially absent.

01 Overview

Structurally, methylboldenone is boldenone with a 17-alpha-methyl group; conceptually it is to boldenone what methandienone (Dianabol) is to testosterone. The methylation grants oral activity at the cost of hepatic strain typical of 17-alkylated steroids.

It has no approved veterinary or human product and is known chiefly from designer-steroid seizures and forum reports. Because it is a boldenone relative, its aromatisation to methylated estrogens and its detection profile are of interest to doping laboratories, but rigorous pharmacology is lacking.

02 Mechanism

Androgen-receptor agonist; the 17-alpha-methyl group resists hepatic first-pass metabolism for oral activity, while the 1,2 double bond confers boldenone-like moderate anabolism.

03 Dosing

TierDoseRouteNotes
Grey-market anecdotal20–40 mg/dayOralNo validated dosing; based on scattered anecdote

Ester comparison

EsterHalf-lifeInjection freq.Testosterone by mass

04 Effects

EffectMagnitudeEvidence
Lean mass and strength gainReported to produce fairly dry gains similar to a milder oral, though unverified.Anecdotal
Oral bioavailability17-alpha-methylation makes an otherwise injectable-class steroid orally active.Preclinical

05 Side effects

EffectSeverityFrequencyEvidenceCountermeasures
HPTA suppressionSuppresses endogenous testosterone via androgen feedback.ModerateExpectedObservational
Hepatotoxicity17-alpha-alkylated structure causes dose- and duration-dependent liver stress, including raised transaminases and cholestasis risk.SevereTypical of 17-alkylated oralsObservational

07 References

Designer anabolic steroids in supplements: analytical reviewDrug Testing and Analysis

08 Discussion0 comments

?
Sign in to add a comment…
Create account
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.